Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $129000.0.

  • Guided Therapeutics' Interest Expenses rose 1944.44% to $129000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $567000.0, marking a year-over-year increase of 7774.29%. This contributed to the annual value of $381000.0 for FY2024, which is 3705.04% up from last year.
  • Per Guided Therapeutics' latest filing, its Interest Expenses stood at $129000.0 for Q3 2025, which was up 1944.44% from $157000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Interest Expenses registered a high of $594000.0 during Q3 2021, and its lowest value of $64000.0 during Q1 2024.
  • In the last 5 years, Guided Therapeutics' Interest Expenses had a median value of $108000.0 in 2024 and averaged $148631.6.
  • Its Interest Expenses has fluctuated over the past 5 years, first tumbled by 7390.57% in 2022, then soared by 12968.75% in 2025.
  • Quarter analysis of 5 years shows Guided Therapeutics' Interest Expenses stood at $100000.0 in 2021, then dropped by 30.0% to $70000.0 in 2022, then rose by 2.86% to $72000.0 in 2023, then surged by 86.11% to $134000.0 in 2024, then decreased by 3.73% to $129000.0 in 2025.
  • Its Interest Expenses was $129000.0 in Q3 2025, compared to $157000.0 in Q2 2025 and $147000.0 in Q1 2025.